Tapentadol

alcohol co-use, benzodiazepine co-use, other opioid co-use, barbiturate co-use, GHB/GBL co-use

Co-administration with any CNS depressant — including alcohol, benzodiazepines, barbiturates, other opioids, GHB/GBL, or general anesthetics — produces additive respiratory and CNS depression with potentially lethal consequences. Fatal outcomes documented in forensic case reports involving co-intoxicants.

paralytic ileus, acute bronchial asthma in unmonitored settings, severe bronchial asthma in unmonitored settings

All standard opioid class contraindications apply, including paralytic ileus and acute or severe bronchial asthma in unmonitored settings without resuscitative equipment available.

epilepsy, predisposition to seizures

Tapentadol is contraindicated in patients with epilepsy or predisposition to seizure disorders. The NRI mechanism lowers seizure threshold. Seizure risk is documented in prescribing information and post-marketing surveillance data.

SSRI co-use, SNRI co-use, TCA co-use, linezolid co-use, methylene blue co-use

Combination with serotonergic drugs increases serotonin syndrome risk. Post-marketing surveillance has not confirmed serotonin syndrome at standard therapeutic doses, but isolated case reports document it in overdose contexts. The risk is lower than with tramadol due to tapentadol's weaker SERT inhibition.

Severe hepatic impairment reduces first-pass glucuronidation via UGT1A9/UGT2B7, increasing bioavailability beyond predictable ranges. Safety and efficacy have not been established in this population.

Safety and efficacy of tapentadol in patients with severe renal impairment have not been established. Tapentadol is excreted almost entirely via the kidneys as conjugated metabolites.

Safety of tapentadol during pregnancy, labor, delivery, and nursing has not been established. Chronic opioid use during pregnancy carries risk of neonatal opioid withdrawal syndrome. Limited post-marketing pregnancy data available; case-by-case evaluation recommended.

Tapentadol is not established for use in children under 18 years in standard tablet formulations. A pediatric oral solution has been evaluated in Phase II/III trials but is not widely approved. Pediatric trial data document nausea (24.2%), vomiting (16.7%), dizziness (9.1%), and headache (6.1%) as common adverse events.

Co-administration with monoamine oxidase inhibitors or use within 14 days of MAOI cessation risks serotonergic and adrenergic toxicity. A mandatory 14-day washout period is required per prescribing information.